Ankyra Therapeutics, Inc
3 clinical trials · Sponsor
◉ Watch Ankyra Therapeutics, Inc
| Record | Firm | Date |
|---|---|---|
| A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma (NCT07100925) | Ankyra Therapeutics, Inc | 2025-12-15 |
| A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer (NCT07027514) | Ankyra Therapeutics, Inc | 2025-10-22 |
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors (NCT06171750) | Ankyra Therapeutics, Inc | 2024-01-19 |
Track Ankyra Therapeutics, Inc automatically
Every clearance here is in the API, with alerts when new ones post.